Entinostat

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

Retrieved on: 
Monday, May 2, 2022
Entinostat, Company, Event, Investor, Twitter, HDAC, Webcast, LinkedIn, Pharmaceutical industry

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Monday, May 9, to discuss the Company's financial results and provide a general business update.
  • The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com .
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 4, 2022
Nasdaq, Twitter, Company, LinkedIn, Board of directors, Entinostat, HDAC, Board, Pharmaceutical industry, Fine chemical

WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on March 1, 2022, of Catherine Madigan, M.D., as Chief Medical Officer, Dr.Madigan received an inducement award to purchase up to 180,000 shares of common stock.

Key Points: 
  • WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on March 1, 2022, of Catherine Madigan, M.D., as Chief Medical Officer, Dr.Madigan received an inducement award to purchase up to 180,000 shares of common stock.
  • Syndax's Board of Directors approved the award as inducement material to Dr.Madigan's employment in accordance with NASDAQ Listing Rule 5635(c)(4).
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 1, 2022
Keck School of Medicine of USC, Private Securities Litigation Reform Act, Dartmouth College, Patient, Entinostat, Medical director, Food and Drug Administration, Industry, Forward-looking statement, Twitter, Food, Syros, U.S. Securities and Exchange Commission, Safety, Rady Children's Hospital, Drug, University, LinkedIn, Medicine, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Company, COVID-19, Alnylam Pharmaceuticals, Risk, Investigational New Drug, University of California, HDAC, Degenerative disease, Pharmaceutical industry, Research, Biogen

WALTHAM, Mass., March 1, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately.

Key Points: 
  • WALTHAM, Mass., March 1, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately.
  • Her appointment is the result of a thorough succession planning process as we lay the groundwork for our evolution into a fully-integrated oncology company.
  • Prior to joining Syros, she served as Senior Medical Director at Alnylam Pharmaceuticals, and was a Medical Director in Biogen's Rare Disease Innovation Unit.
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022

Retrieved on: 
Tuesday, February 22, 2022
Event, Investor, Webcast, LinkedIn, Company, Entinostat, Twitter, Pharmaceutical industry

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Tuesday, March 1, to discuss the Company's financial results and provide a general business update.
  • The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com .
  • Alternatively, the conference call may be accessed through the following:
    For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com .

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

Retrieved on: 
Thursday, February 3, 2022
Private Securities Litigation Reform Act, Safety, Forward-looking statement, Therapy, HDAC, U.S. Securities and Exchange Commission, University, George Washington University, New York University Stern School of Business, R, Twitter, Entinostat, Board of directors, Pfizer, COVID-19, Board, Merck, Drug discovery, Partnership, Acute leukemia, New Drug Application, Georgetown University, Compugen (Israeli company), Company, Clinical Science (journal), Idiopathic pulmonary fibrosis, Business, AstraZeneca, Forest Laboratories, Head, Industry, Biology, LinkedIn, Risk, Medical Affairs Bureau, Maintenance, Management, Pharmaceutical industry, Allergan

Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D).

Key Points: 
  • Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D).
  • Both Mr. Metzger and Dr. Morrison joined Syndax together in 2015 with the goal of building a world-class oncology company.
  • "This transition will better align our roles and priorities with our individual areas of expertise.
  • Prior to joining Syndax, Mr. Metzger served as President, Chief Executive Officer and a Director of Regado Biosciences through its merger with Tobira Therapeutics (acquired by Allergan).

Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update

Retrieved on: 
Monday, January 31, 2022
CEO, Disorder, United Nations, Pembrolizumab, Patient, Ipilimumab, MCRPC, NASDAQ, NUT, University, Audit committee, Immunology, Ovarian cancer, PARP, Biotechnology, Entinostat, Board of directors, Research, BET, Board, NASA, US, Triple-negative breast cancer, Cancer, TSX, Alberta Stock Exchange, Private sector, Colorado State University, GLOBE, Canadian Space Agency, Doctor of Philosophy, Merck, ASCO, US FDA, CDNX, Therapy, Nivolumab, University of California, San Francisco Fetal Treatment Center, First Nations in Ontario, Director, Lymphoma, Management, Pharmaceutical industry, Microbiology, Zenith

CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (Zenith or the Company) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.

Key Points: 
  • CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (Zenith or the Company) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.
  • I am thrilled to be joining Zenith at such an exciting time in the clinical development of its lead compound ZEN-3694, said Dr. Thompson.
  • Dr. Thompsons appointment coincides with Dr. Eldon Smith having stepped down from the Board of Directors, effective today.
  • Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents.

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

Retrieved on: 
Thursday, January 20, 2022
Conference, Entinostat, Twitter, HDAC, LinkedIn, Company, Pharmaceutical industry

WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m.

Key Points: 
  • WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m.
  • ET.
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 7, 2022
Company, HDAC, Entinostat, LinkedIn, Conference, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Twitter, Pharmaceutical industry

WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m.

Key Points: 
  • WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m.
  • A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Retrieved on: 
Monday, December 13, 2021
Adult, U.S. Securities and Exchange Commission, Risk, Forward-looking statement, MLL, CR, Security (finance), Fast Track, Growth, HDAC, Acute lymphoblastic leukemia, SEC, Mixed-phenotype acute leukemia, Private Securities Litigation Reform Act, ALL, Leukemia, COVID-19, Phenotype, Twitter, Publication, Acute myeloid leukemia, Food, Company, LinkedIn, Entinostat, Patient, Safety, CYP3A4, Lists of diseases, DOR, Mutation, Infant, NPM1, FDA, AML, Menin, Pharmaceutical industry

A copy of today's presentation will be available in the Publications and Meeting Presentations section of Syndax's website.

Key Points: 
  • A copy of today's presentation will be available in the Publications and Meeting Presentations section of Syndax's website.
  • In preclinical models of MLLr acute leukemias, SNDX-5613 demonstrated robust, dose-dependent inhibition of tumor growth, resulting in a marked survival benefit.
  • SNDX-5613 is currently being evaluated in the Company's AUGMENT-101 Phase 1/2 open-label clinical trial for the treatment of relapsed/refractory (R/R) acute leukemias.
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Retrieved on: 
Saturday, December 11, 2021
Risk, Food, Cytomegalovirus, Liver, Pharmacology, Epidemiology, Eric Bachier Román, Security (finance), Joint, LinkedIn, Infection, HSCT, Monocyte, Macrophage, U.S. Securities and Exchange Commission, IPF, SEC, Veni, vidi, vici, Fascia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., UCB, COVID-19, Incidence, Society, CMV, CR, Private Securities Litigation Reform Act, Entinostat, Company, Lung, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Survival, ORR, Forward-looking statement, Tissue, Patient, Idiopathic pulmonary fibrosis, Twitter, GVHD, Skin, Orphan, ASH, Safety, NIH, HDAC, Publication, Pharmaceutical industry, Dentistry

"There exists an urgent need for novel and effective therapies in patients with cGVHD," said Michael Meyers, M.D, M.P.H., Chief Medical Officer of Syndax.

Key Points: 
  • "There exists an urgent need for novel and effective therapies in patients with cGVHD," said Michael Meyers, M.D, M.P.H., Chief Medical Officer of Syndax.
  • "The broad activity and tolerability observed underscores axatilimab's potential to play a meaningful role in the cGVHD treatment landscape, and further supports the importance of the ongoing AGAVE-201 trial."
  • Enrollment is ongoing in the Company's global pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD, with topline data expected in 2023.
  • ASH annual meeting 2019; abstract #2109 Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: AU.S.Claims Analysis.